On GLP-1s Before Surgery: Should You Stop or Stay the Course?

On GLP-1s Before Surgery: Stop or Stay the Course? A Real Decision Guide

Here's a situation more people are running into than you'd think: you've been on semaglutide or tirzepatide for months, you've made real progress, and now you're scheduled for surgery. Your prescriber says stop. Another doctor says the risk is overblown. The internet gives you seventeen conflicting opinions.

A new 10-year retrospective study looked specifically at patients on GLP-1 receptor agonists who underwent abdominal panniculectomy — that's the surgery to remove excess skin after major weight loss. The findings are more nuanced than the blanket "stop your GLP-1 two weeks before surgery" advice you've probably heard.

Important: I'm not a doctor. Everything I share here is based on published research and my own reading of the literature. Talk to your physician before making any changes to your medication regimen — especially around surgery.

---

The Bottom Line

• A 10-year retrospective analysis of panniculectomy patients found that GLP-1 receptor agonist use around the time of surgery was associated with measurable differences in surgical outcomes compared to non-users.
• The biggest documented concern isn't bleeding or wound infection — it's aspiration risk during anesthesia, because GLP-1s slow stomach emptying (gastroparesis effect).
• Current guidance from the American Society of Anesthesiologists recommends pausing GLP-1s before elective surgery — but the optimal window is still debated.
• If you're on a GLP-1 and have surgery scheduled, the actionable step is simple: bring it up with both your prescriber AND your anesthesiologist, not just one of them.
• This is not a reason to panic or quit your medication. It's a reason to have a more specific conversation than most patients are having.

---

What Is a Panniculectomy, and Why Does This Study Matter?

A panniculectomy removes the apron of loose skin that hangs over the abdomen after significant weight loss. It's not a cosmetic procedure — it's often medically necessary to prevent chronic skin infections, rashes, and mobility problems.

Here's why this patient population is uniquely important for studying GLP-1 surgery risks: these are people who lost weight because of GLP-1s, and then pursued surgery as a next step. They're likely still on GLP-1 medications at the time of their procedure.

This isn't a hypothetical overlap. It's an increasingly common clinical situation, and until recently, almost no one had studied what that combination actually looks like over a long time horizon.

The 10-year retrospective analysis published on PubMed fills that gap. It pulled real-world data from patients who had panniculectomy procedures over a decade, comparing those on GLP-1 receptor agonists perioperatively (meaning around the time of surgery) versus those who were not.

---

The Two Options You're Weighing

If you're on a GLP-1 and facing surgery, the real decision isn't as simple as "stop" or "don't stop." It's actually more like:

Option A: Pause your GLP-1 before surgery, per standard anesthesia guidance. You reduce aspiration risk during the procedure. You may experience some appetite rebound. Your blood sugar management (if you're diabetic) may need temporary adjustment.

Option B: Continue your GLP-1 through the surgical period. You maintain metabolic stability and appetite control. But you carry higher residual gastric content risk under anesthesia — and the data suggests real consequences if that goes wrong.

Let's break down what the research actually says about each path.

---

What the 10-Year Study Found

The retrospective analysis tracked surgical outcomes specifically in nonbariatric abdominal panniculectomy — meaning this wasn't weight-loss surgery itself, it was the reconstructive step that often follows it.

Patients on GLP-1 receptor agonists perioperatively showed differences in several outcome categories compared to those not on GLP-1s at the time of surgery.

Here's what that means in plain terms:

On complication rates: The GLP-1 group did not show dramatically higher rates of wound complications or infection in this particular cohort — which surprised some researchers. That's actually somewhat reassuring for patients worried about healing.

On aspiration and anesthesia safety: This is where the concern lives. GLP-1 receptor agonists are known to slow gastric emptying. That's part of why they reduce appetite — food stays in your stomach longer and you feel full. But under general anesthesia, a stomach that isn't fully empty is a risk factor for aspiration pneumonia, which is when stomach contents enter the lungs. That's a serious, sometimes fatal complication.

The study's findings are consistent with what the American Society of Anesthesiologists flagged in their 2023 guidance, recommending that patients on weekly GLP-1 injections hold their dose for one week before elective procedures, and daily GLP-1 users hold for one day.

On blood sugar control: For diabetic patients, stopping a GLP-1 medication perioperatively can create a gap in glucose management. The retrospective data showed this is a real tradeoff — not just a theoretical one.

---

Why the "Just Stop It" Advice Is Too Simple

The blanket recommendation to pause GLP-1s before surgery is well-intentioned. But it doesn't account for the full picture.

First, stopping a GLP-1 isn't like stopping a vitamin. These medications change how your body processes hunger, insulin, and gastric motility over time. Abruptly stopping before surgery can mean a sudden return of appetite, potential blood sugar instability in metabolic patients, and a disrupted recovery window.

Second, the aspiration risk — while real — is dose-dependent and patient-dependent. Someone on a low dose of semaglutide who has been stable for months has a different gastric motility profile than someone who just started a high dose of tirzepatide and is still in the nausea phase.

Third, the research distinguishes between elective procedures and urgent ones. For emergency surgery, you can't always pause medications. Anesthesiologists need to know you're on a GLP-1 so they can use extended fasting protocols and precautionary airway management — not so they can cancel the procedure.

A 2026 review of GLP-1 receptor agonists in The New England Journal of Medicine by Rosen and Ingelfinger summarizes the current clinical understanding well: these are powerful medications with systemic effects that extend well beyond blood sugar. Their perioperative implications are still being mapped.

---

Who Should Lean Toward Pausing (Option A)

You're a stronger candidate for pausing your GLP-1 before surgery if:

• You're having an elective procedure with a scheduled date (gives you time to plan)
• You're on a weekly injectable like semaglutide or tirzepatide at a moderate to high dose
• You have any history of gastroparesis or slow gastric emptying
• You're not diabetic — meaning the medication is primarily for weight management, not glucose control
• Your surgery involves general anesthesia (versus local or regional)

In these cases, working with your prescriber to pause 1–2 weeks before the procedure aligns with current anesthesia guidance, and the metabolic disruption is manageable with planning.

---

Who Has a More Complicated Decision (Option B Context)

The calculus gets harder if:

• You have Type 2 diabetes and your GLP-1 is doing significant glucose management work. Stopping abruptly can create real hyperglycemia risk around surgery.
• You're in the middle of a dose escalation and stopping means restarting the titration process, which is disruptive and sometimes means months of delayed therapeutic benefit.
• Your surgery is semi-urgent and can't wait weeks for a washout period.
• You have a history of severe weight regain when off GLP-1s, and your surgical candidacy depends on maintaining your current weight.

In these situations, the conversation between you, your surgeon, and your anesthesiologist needs to be specific — not a quick checkbox. The 10-year retrospective data gives your care team real-world outcomes to reference, not just theoretical risk models.

---

The Aspiration Risk Explained Simply

Here's the thing most patients don't fully understand: the danger isn't that GLP-1s make surgery go wrong in general. The specific, documented danger is what happens during intubation.

When you go under general anesthesia, your airway protective reflexes shut off. If your stomach still has food or liquid in it, there's a chance it can come up and enter your lungs. This is called aspiration, and it can cause a severe form of pneumonia.

GLP-1s slow the rate at which your stomach empties. So even if you followed standard "nothing by mouth after midnight" fasting instructions, your stomach might still have residual content because the medication slowed emptying beyond what normal fasting would clear.

That's why anesthesiologists want to know you're on these medications. And it's why the guidance is specifically about extended fasting windows or procedural precautions — not about the medications being dangerous to your heart or organs during surgery.

---

What the Panniculectomy Data Adds to the Conversation

Most existing surgical safety discussions about GLP-1s have focused on bariatric (weight-loss) surgery itself. This study is different because panniculectomy is a downstream procedure — it happens after the weight loss has already occurred.

That distinction matters for a few reasons.

Patients at this stage have often been on GLP-1 medications for longer. Their bodies have adapted to the gastric motility effects. Their metabolic profiles are more stable. The risk calculus is different from someone just starting semaglutide who is also having emergency abdominal surgery.

The 10-year retrospective design also captures real-world variation that clinical trials can't. It includes patients who did pause, patients who didn't, patients across dose ranges, and outcomes over a decade. That breadth makes the findings more applicable to actual clinical decisions.

The bottom line from the data: GLP-1 use around the time of panniculectomy does not appear to dramatically worsen wound outcomes, but the anesthesia and aspiration risk remains the primary concern that needs active management.

---

What to Actually Say to Your Doctor

Most patients go into pre-surgical appointments and mention their medications passively. "Oh, I'm on Ozempic" as an afterthought.

Here's a more useful approach. Ask these specific questions:

1. "Given that I'm on [your GLP-1], should I pause it before surgery — and for how long?"
2. "Do you recommend an extended fasting window before my procedure because of the gastric emptying effects?"
3. "Will my anesthesiologist know I'm on this medication?"
4. "If I pause, how do I manage [blood sugar / appetite / dosing restart] in the window before and after?"

You're not second-guessing your surgeon. You're making sure the right information gets to the right people. The retrospective data shows that outcomes differ based on perioperative GLP-1 use — which means your medical team needs to know and plan accordingly.

---

FAQ

Should I stop Ozempic before surgery? Current guidance from the American Society of Anesthesiologists recommends pausing weekly GLP-1 injections like semaglutide (Ozempic/Wegovy) for at least one week before elective surgery. This is primarily to reduce the risk of aspiration during anesthesia. Talk to both your prescriber and your anesthesiologist to make a plan tailored to your situation.

What happens if I take semaglutide the week before surgery? Semaglutide slows gastric emptying, which means your stomach may not be fully empty even with standard overnight fasting. This increases aspiration risk during general anesthesia. It doesn't mean the surgery can't happen, but your anesthesiologist needs to know so they can take precautions.

Does stopping a GLP-1 before surgery affect blood sugar? For people using GLP-1s to manage Type 2 diabetes, stopping the medication can temporarily raise blood sugar levels around the time of surgery. This is a real tradeoff that needs active management. Your care team should have a plan for glucose monitoring and control during the perioperative period.

Is panniculectomy safe if you've been on GLP-1 medications long-term? According to the 10-year retrospective analysis, wound complication rates in GLP-1 users were not dramatically elevated compared to non-users. The primary concern remains aspiration risk from slowed gastric emptying, not wound healing. That said, individual outcomes vary significantly based on dose, duration, and patient health history.

How long do GLP-1s affect gastric emptying after you stop? This depends on the specific medication and your dose. Weekly injectables like semaglutide have a long half-life — the effects on gastric motility can persist for days after the last dose. That's why a one-week pause is the current recommendation, not just skipping the day-of dose.

---

The Bottom Line: This Is a Planning Problem, Not a Panic Problem

If you're on a GLP-1 and you have surgery coming up, the research is actually giving you actionable information.

You're not in a crisis. You're in a planning conversation.

The 10-year panniculectomy data adds real-world weight to what was previously mostly theoretical anesthesia concern. GLP-1s don't appear to make surgical healing significantly worse — but they do create a specific, manageable aspiration risk that your care team needs to know about and plan around.

Stop treating this as a disclosure to mumble at the end of a pre-op appointment. Make it a conversation. Bring up the ASA guidance. Ask about your specific fasting window. Confirm your anesthesiologist has been flagged.

That's the move. Not quitting your medication in a panic. Not hiding it hoping nothing goes wrong.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.

---

Sources

1. Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis — PubMed, 2025
2. GLP-1 Receptor Agonists — Rosen & Ingelfinger — The New England Journal of Medicine, 2026
3. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative GLP-1 Use — ASA, 2023
4. Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis — Endocrine Practice, 2026
5. Target Trial Emulations for Tirzepatide, Semaglutide, and SGLT2-Inhibitors for Dementia — Diabetes Research and Clinical Practice, 2026